STAMFORD, Conn., July 17, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc., a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced today several key executive appointments across Finance, R&D and Corporate Development. Joining the company are Dov Goldstein, MD as Chief Financial Officer; Jennifer Low, MD, PhD as Executive Vice President of Research & Development; and Jacob Van Naarden as Vice President of Corporate Development & Strategy.
"We are excited to announce these additions to the Loxo Oncology team," said Josh Bilenker, MD, Chief Executive Officer. "Dov, Jennifer and Jake bring a wealth of business and drug development experience to the company. This expansion of financial, regulatory, development and operational expertise comes at an important inflection point for Loxo. Our new team members will be instrumental to the success of the LOXO-101 clinical program and the further advancement of our drug candidate pipeline."
Dov Goldstein, MD, Chief Financial Officer
In addition to his new role as Chief Financial Officer, Dr. Goldstein also serves on the Loxo Oncology Board of Directors. Dr. Goldstein is an Operating Partner at Aisling Capital and was most recently a Partner at Aisling, responsible for leading and managing investments in numerous therapeutic companies. Dr. Goldstein previously served as Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals. He helped lead Vicuron through its initial public offering and its acquisition by Pfizer.
Jennifer Low, MD, PhD, Executive Vice President, R&D
Dr. Low most recently served as Senior Group Medical Director in Product Development at Genentech, a member of the Roche Group. In that role, Dr. Low led the development of Erivedge (vismodegib, the first approved hedgehog pathway inhibitor) from the first-in-man study to global approvals, and supervised the development teams for numerous drugs and drug candidates including Zelboraf (vemurafenib, the first approved inhibitor of BRAF V600), Tarceva (erlotinib, EGFR inhibitor) and cobimetinib (GDC-0973, MEK1/2 inhibitor). Prior to Genentech, Dr. Low was a Senior Investigator in the Investigational Drug Branch of the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute (NCI) and an attending physician at the National Institutes of Health Clinical Center in Bethesda, Maryland.
Jacob Van Naarden, Vice President, Corporate Development & Strategy
Mr. Van Naarden most recently served as a public equity biotechnology analyst at HealthCor Management, an investment firm focused on companies across all sectors of the healthcare and life sciences industry. Prior to HealthCor, Mr. Van Naarden was an Associate at Aisling Capital. Mr. Van Naarden started his career as an Investment Banker in the Healthcare Group at Goldman Sachs.
About Loxo Oncology
Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, MD. Loxo Oncology is committed to rapidly bringing to the clinic targeted cancer therapies that have an opportunity for clinical success in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. For more information, visit www.loxooncology.com.
CONTACT: Jacob Van Naarden Vice President firstname.lastname@example.orgSource: Loxo Oncology